EZH2 and breast carcinoma: Puppe et al. reported that BRCA-1-deficient breast cancer, which overexpress EZH2, was 20-fold more effective compared to BRCA-proficient breast cancer cell lines when the H3K27me3 selective inhibitor DZNep was used [24].